RAD 1601: EDGE Radiosurgery for Intractable Essential Tremor and Tremor-Dominant Parkinson's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03305588|
Recruitment Status : Recruiting
First Posted : October 10, 2017
Last Update Posted : January 18, 2020
|Condition or disease||Intervention/treatment||Phase|
|Essential Tremor Parkinson Disease||Device: Unframed Virtual Cone||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||RAD 1601: Pilot Trial of Frameless Virtual Cone Stereotactic Radiosurgical Thalamotomy for Intractable Tremor and Advanced Functional Connectivity Parcellation of the Thalamus|
|Actual Study Start Date :||December 5, 2017|
|Estimated Primary Completion Date :||November 2021|
|Estimated Study Completion Date :||November 2021|
Experimental: 130 Gy Radiation & Unframed Virtual Cone
130 Gy Virtual Cone Radiosurgery Unframed (Face Mask)
Device: Unframed Virtual Cone
The patient will undergo stereotactic radiosurgery. Radiosurgery is a single non-surgical radiation treatment and will be done as an outpatient procedure. High-energy radiation will be delivered to a small, precise area of the patient's brain using a linear accelerator. A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. During the procedure, the study doctor will confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on a small area in the thalamus of the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is 30 to 60 minutes. The face mask will be removed after the treatment.
- Overall tremor reduction proportion evaluated by the Fahn-Tolosa-Marin Tremor Rating Scale (FTMTRS) [ Time Frame: From Baseline up to 1 Year following completion of radiosurgery ]The Fahn-Tolosa-Marin Tremor Rating Scale evaluation will assess the severity of the patient's tremor and measure the impact on their activities of daily living.
- Number of Participants with treatment-related adverse events [ Time Frame: From Baseline up to 1 Year following completion of radiosurgery ]Based on the assessments of the patient and the responses provided by the patient in questionnaires, the investigators will assess acute and late neurologic toxicities. All adverse events/toxicities will be assessed with the utilization of CTCAE v.4.0.
- Changes in resting-state functional MRI (fMRI) and diffusion tensor patterns associated with Radiosurgical thalamotomy [ Time Frame: From Baseline up to 1 Year following completion of radiosurgery ]Changes will be assessed by resting-state functional MRI (fMRI) to see the impact of radiosurgery ablation on brain function or alteration of function of the ventral intermediate nucleus of the thalamus.
- Mean of Quality of Life Scores measured by SF-36 questionnaire [ Time Frame: From Baseline up to 1 Year following completion of radiosurgery ]Quality of Life (QOL) will be measured by SF-36 questionnaire. This questionnaire consists of 36 questions (items) measuring physical and mental health in relation to 8 health concepts: physical functioning, bodily pain, role of limitations due to physical health problems, role of limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perception. All items are scored so that a high score defines a more favorable health state. Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are set at 0 and 100, respectively.
- Mean of Quality of Life Scores measured by PROMIS Upper Extremity Questionnaire [ Time Frame: From Baseline up to 1 Year following completion of radiosurgery ]PROMIS Upper Extremity questionnaire will assess effect of tremor on one's physical function of upper extremity, as well as, effects on activities of daily living.
- Patient Satisfaction Scores [ Time Frame: 3 Month Follow-Up Visit ]3 months following the completion of radiosurgery, the patient will be asked the following two questions: 1) Would the participant have the radiosurgery procedure again? 2) Would the participant recommend it to friends and family?
- Define Targeting Methods within Thalamus based on Structural and Functional Connectivity [ Time Frame: From Baseline up to 1 Year following completion of radiosurgery ]Compare how well the standard MRI conventional thalamotomy targeting technique (based on predetermined atlas coordinates) matches with advanced MRI-based (functional and structural) mapping of the thalamotomy target.
- Mean of Quality of Life Scores measured by TRG Essential Tremor Rating Assessment Scale (TETRAS) [ Time Frame: From Baseline up to 1 Year following completion of radiosurgery ]TETRAS scale will assess 9 performance items of examination to create a clinical rating scale for essential tremor.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03305588
|Contact: Laronica Conway||(205) email@example.com|
|Contact: Kristin Webbfirstname.lastname@example.org|
|United States, Alabama|
|University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center||Recruiting|
|Birmingham, Alabama, United States, 35249|
|Principal Investigator: Markus Bredel, MD, PhD|
|Sub-Investigator: Harrison Walker, MD|
|Sub-Investigator: Barton Guthrie, MD|
|Sub-Investigator: Frank Skidmore, MD|
|Sub-Investigator: Erik Middlebrooks, MD|
|Sub-Investigator: John Fiveash, MD|
|Sub-Investigator: Evan Thomas, MD, PhD|
|Sub-Investigator: Asim Bag, MD|
|Sub-Investigator: Victor Sung, MD|
|Principal Investigator:||Markus Bredel, MD, PhD||University of Alabama at Birmingham|